CN102341111A - 磷酸盐吸附剂 - Google Patents

磷酸盐吸附剂 Download PDF

Info

Publication number
CN102341111A
CN102341111A CN2010800106646A CN201080010664A CN102341111A CN 102341111 A CN102341111 A CN 102341111A CN 2010800106646 A CN2010800106646 A CN 2010800106646A CN 201080010664 A CN201080010664 A CN 201080010664A CN 102341111 A CN102341111 A CN 102341111A
Authority
CN
China
Prior art keywords
compositions
calcium
aforementioned
magnesium
ferrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800106646A
Other languages
English (en)
Chinese (zh)
Inventor
G·维策尔
P·盖泽尔
E·菲利普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102341111(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of CN102341111A publication Critical patent/CN102341111A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800106646A 2009-03-02 2010-03-01 磷酸盐吸附剂 Pending CN102341111A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09154107.8 2009-03-02
EP09154107 2009-03-02
PCT/EP2010/052551 WO2010100112A1 (en) 2009-03-02 2010-03-01 Phosphate adsorbent

Publications (1)

Publication Number Publication Date
CN102341111A true CN102341111A (zh) 2012-02-01

Family

ID=40627528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800106646A Pending CN102341111A (zh) 2009-03-02 2010-03-01 磷酸盐吸附剂

Country Status (20)

Country Link
US (1) US20120052135A1 (enExample)
EP (1) EP2403506A1 (enExample)
JP (1) JP2012519201A (enExample)
KR (1) KR101497003B1 (enExample)
CN (1) CN102341111A (enExample)
AR (1) AR076070A1 (enExample)
AU (1) AU2010220396B2 (enExample)
BR (1) BRPI1009110A2 (enExample)
CA (1) CA2753364A1 (enExample)
CL (1) CL2011002130A1 (enExample)
IL (1) IL214509A0 (enExample)
MX (1) MX2011009144A (enExample)
MY (1) MY162484A (enExample)
NZ (1) NZ594730A (enExample)
PE (1) PE20120327A1 (enExample)
RU (1) RU2527682C2 (enExample)
SG (1) SG173887A1 (enExample)
TW (1) TWI454267B (enExample)
WO (1) WO2010100112A1 (enExample)
ZA (1) ZA201106305B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105232767A (zh) * 2015-09-29 2016-01-13 江苏锦宇环境工程有限公司 一种制备吸附磷酸盐的药物制剂的方法
CN107397758A (zh) * 2016-05-19 2017-11-28 欣凯医药化工中间体（上海）有限公司 一种磷结合剂及其制备方法
CN107397760A (zh) * 2016-05-19 2017-11-28 欣凯医药化工中间体（上海）有限公司 基于铁的氢氧化物－低分子量糖的磷结合剂、其制备方法及其应用
CN113029978A (zh) * 2019-12-25 2021-06-25 远大生命科学(辽宁)有限公司 一种检测含镧试剂的磷结合能力的方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
EP2548562A1 (de) 2011-07-18 2013-01-23 SeBo GmbH Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern
CN109497565B (zh) * 2013-03-08 2021-10-26 上海礼邦医药科技有限公司 金属离子-功能性纤维组分络合物组合物、其制备及用途
EP2805603B1 (de) * 2013-05-22 2017-01-11 CLAAS E-Systems KGaA mbH & Co KG Vorrichtung und Verfahren zur Überwachung der Schneidenschärfe
WO2015181205A1 (en) 2014-05-28 2015-12-03 Biaqua B.V. Method for removing phosphate from water fractions
BR112019024907A2 (pt) 2017-05-31 2020-06-23 Mars, Incorporated Métodos de diagnóstico e tratamento de doença renal crônica
EP3930686B1 (en) 2019-02-28 2023-05-31 Renibus Therapeutics, Inc. Novel iron compositions and methods of making and using the same
US20210130251A1 (en) * 2019-07-17 2021-05-06 Water Warriors Inc. Adsorbent Structures for the Removal of Phosphates and Ammonia from Wastewater and Methods of Use
EP3958689A1 (en) * 2019-07-23 2022-03-02 Société des Produits Nestlé S.A. Methods and compositions with renal benefits for felines
CN111905736B (zh) * 2020-07-23 2021-10-26 安徽工业大学 一种半胱氨酸功能化改性的羟基氧化铁、电催化剂、制备方法及应用
WO2025176793A1 (en) * 2024-02-21 2025-08-28 Mars, Incorporated Food composition for treating mineral bone disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
CN1270526A (zh) * 1997-09-19 2000-10-18 克罗斯菲尔德有限公司 作为磷酸盐结合剂的混合或硫酸化的金属化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547356A1 (de) * 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
DE19917705C1 (de) * 1999-04-20 2000-12-28 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
EP1932808A1 (en) * 2006-12-14 2008-06-18 Novartis AG Iron(III)-Carbohydrate based phosphate adsorbent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
CN1270526A (zh) * 1997-09-19 2000-10-18 克罗斯菲尔德有限公司 作为磷酸盐结合剂的混合或硫酸化的金属化合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105232767A (zh) * 2015-09-29 2016-01-13 江苏锦宇环境工程有限公司 一种制备吸附磷酸盐的药物制剂的方法
CN107397758A (zh) * 2016-05-19 2017-11-28 欣凯医药化工中间体（上海）有限公司 一种磷结合剂及其制备方法
CN107397760A (zh) * 2016-05-19 2017-11-28 欣凯医药化工中间体（上海）有限公司 基于铁的氢氧化物－低分子量糖的磷结合剂、其制备方法及其应用
CN113029978A (zh) * 2019-12-25 2021-06-25 远大生命科学(辽宁)有限公司 一种检测含镧试剂的磷结合能力的方法

Also Published As

Publication number Publication date
MY162484A (en) 2017-06-15
CA2753364A1 (en) 2010-09-10
KR101497003B1 (ko) 2015-02-27
AU2010220396A1 (en) 2011-09-01
RU2011140017A (ru) 2013-04-10
WO2010100112A1 (en) 2010-09-10
EP2403506A1 (en) 2012-01-11
AR076070A1 (es) 2011-05-18
TW201034677A (en) 2010-10-01
JP2012519201A (ja) 2012-08-23
PE20120327A1 (es) 2012-04-11
US20120052135A1 (en) 2012-03-01
MX2011009144A (es) 2011-09-15
NZ594730A (en) 2013-06-28
CL2011002130A1 (es) 2012-03-23
BRPI1009110A2 (pt) 2019-09-24
KR20110128329A (ko) 2011-11-29
IL214509A0 (en) 2011-09-27
RU2527682C2 (ru) 2014-09-10
ZA201106305B (en) 2012-05-30
SG173887A1 (en) 2011-10-28
AU2010220396B2 (en) 2013-10-17
TWI454267B (zh) 2014-10-01

Similar Documents

Publication Publication Date Title
CN102341111A (zh) 磷酸盐吸附剂
CN100549015C (zh) 氨基酸螯合物的制备方法
JP2614909B2 (ja) カルシウム化合物およびクエン酸の易溶性混合物からの液体カルシウム補充
Mills et al. Metabolic consequences of continent urinary diversion
Mai et al. Calcium acetate, an effective phosphorus binder in patients with renal failure
US8216614B2 (en) Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
Porena et al. Prevention of stone disease.
Loghman-Adham Phosphate binders for control of phosphate retention in chronic renal failure
JPS62501846A (ja) 液体食事カルシウム補足
CA2624619C (en) Improved toleration iron supplement compositions
US20040048925A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
Funk et al. Interactions Between Iron (III)-hydroxide Polymaltose Complex and Commonly Used Medications
US20040220266A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20060228424A1 (en) Phosphorus binder for treatment of kidney disease
Kopple Nutrition and the kidney
WO2009076742A1 (en) Effervescent dietary composition for enhancing delivery of dietary ingredients
Jepson Disorders of phosphorus and magnesium
US12251400B2 (en) Liquid concentrates of calcium and magnesium
Bernstein Improving Magnesium Absorption and Bioavailibility
CN101505766A (zh) 磷障碍预防改善治疗剂、用于吸附食品或药品中的磷酸离子的口服剂及它们的制造方法
WO2005096846A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20090239914A1 (en) Phosphorus binder for treatment of renal disease
Schlussel Mineral Absorption and deficiency
Gallagher et al. Calcium and vitamin D
Shapses et al. That Impact Mineral Status

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120201